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Abstract 
Advances in cardiac imaging have resulted in greater recognition of cardiac 
amyloidosis (CA) in everyday clinical practice, but the diagnosis continues to be made 
in patients with late stage disease, suggesting that more needs to be done to improve 
awareness of its clinical manifestations and the potential of therapeutic intervention to 
improve prognosis.  Light chain CA (AL-CA) in particular, if recognized early and treated 
with targeted plasma cell therapy, can be managed very effectively. For patients with 
transthyretin amyloidosis, there are numerous therapies that are currently in late phase 
clinical trials. In this review we address common questions encountered in clinical 
practice regarding etiology, clinical presentation, diagnosis and management of cardiac 
amyloidosis, focusing on recent important developments in cardiac imaging and 
biochemical diagnosis. The aim is to show how a systematic approach to the evaluation 
of suspected CA can impact the prognosis of patients in the modern era. 
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Introduction 
What is amyloidosis?:  Amyloidosis is a localized or systemic deposition disease in 
which proteins with unstable tertiary structures misfold, aggregate and form amyloid 
fibrils that deposit with a range of chaperone proteins in the heart, kidneys, liver, 
gastrointestinal tract, lungs and soft tissues1. Individual amyloid fibrils are non-
branching, 7 to 10 nm in width and of variable length.  They are insoluble and notably 
resistant to proteolysis2. The term “lardaceous disease” was first used to describe such 
deposits at autopsy but was replaced by the botanical term “amyloid” because of their 
starch-like affinity for iodine3. In polarized light under the microscope, the deposits, 
when stained with the dye Congo red, display apple-green birefringence, changing from 
a hyaline pink appearance in normal light4. Under  electron microscopy amyloid fibrils 
appear as  needle-like structures with multiple filaments that have a unique highly 
organized cross β-pleated-sheet configuration5.. Among the signature chaperone 
proteins found in all amyloid deposits are the pentraxin serum amyloid P component 
(SAP), clusterin, vimentin, vitronectin, glycosaminoglycans and apolipoproteins6. 
 
What forms of amyloidosis affect the heart? There are more than thirty proteins that 
can form amyloid fibrils, five of which frequently infiltrate the heart and cause CA: 
immunoglobulin light chain (AL or primary amyloidosis), immunoglobulin heavy chain 
(AH), transthyretin (ATTR), serum amyloid A (AA), and apolipoprotein A I (AApoA1). 
The overwhelming majority of patients with CA are affected by either AL or ATTR CA. 
While the general mechanism of extracellular deposition of fibrillary proteins leading to 
tissue and organ dysfunction is common to all forms of CA, there are three major 
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precursor proteins causing CA, each with differing natural histories and therapies  
including AL and ATTR due to a mutation (ATTRm) or wild type (ATTRwt).7 
 
Epidemiology and Delays in Diagnosis 
Is cardiac amyloidosis rare? AL-CA is a rare condition with an estimated prevalence 
of 8 to 12 per million8-10.  There are ~3,000 newly diagnosed cases of AL amyloid per 
year in the United States (US) of which 30-50% of which have symptomatic cardiac 
involvement and 10-15% occur in association with multiple myeloma11.  There are 
currently ~10,000 individuals affected with AL in the US, consistent with the definition of 
an orphan disease as one that affects less than 200,000 persons. The population 
prevalence of ATTR-CA is less certain, but recent data suggest that it is overlooked as 
a cause of common cardiovascular conditions in older people including heart failure with 
preserved ejection fraction (HFpEF), low flow aortic stenosis and atrial fibrillation12, 13.  
Autopsy data has demonstrated that among adults more than 80 years of age, 25% 
have transthyretin amyloid deposits in the myocardium14.  Among patients with HFpEF, 
autopsy data reveal amyloid deposits in 32% of those over 75 years of age compared 
with 8% of those aged <75 years (8%)15, 16.  Emerging data using nuclear scintigraphy 
has suggested that 13% (95% CI 7.2-19.5%) of patients hospitalized with HFpEF may 
have ATTRwt-CA17. Some patients, however, have disease caused by mutations in the 
TTR gene and although these are relatively rare, some genetic forms are endemic in 
particular geographic regions. The Val122Ile mutation, which almost exclusively affects 
individuals of African or Afro-Caribbean descent, has a population prevalence of 3-4%18 
and while clinical penetrance of this variant is incomplete in subjects up to 80 years of 
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age, it is almost certainly under-recognized as a cause of heart failure19.  Emerging data 
suggest that ATTR-CA, especially due to ATTRwt, is not uncommon and will become 
the most commonly diagnosed form of CA. 
 
How often is the diagnosis missed or delayed? CA is often misdiagnosed and the 
delayed diagnosis has significant consequences for patients.  In a survey of more than 
500 patients with AL (37% of whom had cardiac involvement) the average time from 
initial symptoms to diagnosis was 2 years. A substantial proportion of patients (31.8%) 
reported seeing at least 5 physicians before receiving a diagnosis of amyloidosis. 
Cardiologists were consulted more often than hematologists, oncologists or 
nephrologists, but were responsible for making the diagnosis in only 18.7% of cases. 
Similar data for ATTR-CA, albeit in much smaller populations, reveals that less than half 
of subjects were diagnosed within 6 months, mainly by cardiologists.20 
 
What are the impediments to early and accurate diagnosis? CA is a “great 
pretender”, often misdiagnosed as another condition or delayed in its recognition as a 
result of both physician and disease related factors. Optimum diagnosis and care 
requires multidisciplinary management (cardiology, neurology, nephrology and 
hematology) but amyloidosis teams are relatively few. Additionally, the absence of 
disease modifying therapies for ATTR and the late presentation of AL-CA patients has 
contributed to a nihilistic attitude about the condition. 
The main disease-related factor that hinders a correct and timely diagnosis is 
heterogeneity with respect to the cardiac phenotype as well as systemic involvement. 
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The need for a histological demonstration of target organ amyloid infiltration has also 
delayed the diagnosis as the technique is restricted to referral centers with expertise in 
the performance of endomyocardial biopsy and requires skilled pathologic analysis of 
obtained samples.  Phenotypic variability of genetic forms of ATTR is also influenced by 
genetic heterogeneity, geography, endemic vs. non-endemic aggregation, age, sex of 
the patient and transmitting parent, and probably amyloid fibril composition21, 22 23.  
Patients also rarely report a family history because of the late presentation and 
incomplete penetrance.  
 
In whom should one consider cardiac amyloid? The diagnosis of CA requires a high 
index of clinical suspicion.  In the past, the presence of multi-organ involvement was 
over-emphasized, resulting in consideration of the diagnosis only in the presence of 
extreme extra-cardiac findings such as macroglossia and periorbital purpura that while 
specific, are present only in a minority of AL cases and absent in ATTR-CA.  A number 
of diagnostic red flags (Table 1) in a patient with otherwise unexplained left ventricular 
hypertrophy or restrictive cardiomyopathy can foster the correct suspicion. A history of 
carpal tunnel syndrome in ATTR (particularly if bilateral in a male), atraumatic rupture of  
biceps tendon, unexplained neuropathic pain, orthostatic hypotension and a diagnosis 
of “hypertrophic cardiomyopathy” after the 6th decade of life are useful clues. 
 
Key point: Increased awareness of cardiac amyloidosis is essential to reduce 
under-diagnosis and misdiagnosis, which is critical because prognosis worsens 
rapidly with advancing organ dysfunction. 
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Pathophysiology and Natural History 
Why is the heart affected in some cases of amyloidosis and not others?  The 
heterogeneity of systemic amyloidosis remains puzzling. Patients with the same type of 
amyloidosis, whether AL or ATTR, can have different patterns of organ involvement and 
different amounts of amyloid in the involved organs. Patients with systemic AL 
amyloidosis without heart involvement at diagnosis are likely to develop cardiac 
involvement if their culprit light-chain proteins are not eliminated and if they live long 
enough30.  The basis for the organ tropism of AL is not known. Studies of the 
immunoglobulin light-chain genetic clones underlying AL indicate that the repertoire of 
light-chain germline genes used in AL is restricted; four light-chain variable region 
germline genes (IGKV1-16, IGLV6-57, IGLV2-14, IGLV3-1) account for two thirds of 
cases, and there is  tropism for the heart with IGLV2-14 and IGLV3-131-35 although the 
mechanism  is unknown36. The explanation for the differential involvement of the heart 
and peripheral nervous system in patients with ATTR is also unexplained. 
 
What is the natural history of ATTR cardiac amyloidosis? ATTR-CA may be due to 
specific mutations that have a predominant involvement of the heart (Val122Ile, 
Leu111Met, Ile68Leu) or ATTRwt (Table 2).  Ile68Leu and Leu111Met are mutations 
reported almost exclusively in Italy and Denmark, respectively, causing a severe 
cardiomyopathy at an early age with a malignant course22, 37, 38.  In the US, ATTRwt 
followed by Val122Ile and Thr60Ala mutation forms are most common39. Original 
reports7, 40, 41 suggested that ATTRwt-CA had a median survival of >5 years. However, 
recent reports42-44 have demonstrated that outcomes are worse with median survivals of 
~3.5 years after initial evaluation45. These discrepancies are in part related to difficulty 
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in defining when the disease begins.  Initial manifestations of TTR deposits often 
include bilateral carpal tunnel syndrome46, which is found in ~70% of individuals with 
ATTRwt-CA on average 5-7 years prior to the cardiac manifestations.  Other 
manifestations include atrial arrhythmias and a progressive decline in effort tolerance, 
which are difficult to definitively attribute to amyloidosis as they occur commonly with 
advancing age. However, it is clear that ATTRwt-CA can manifest as early as the fifth 
decade of life. Cohort studies among subjects with ATTR-CA are predominately single 
center reports42, 44, 47.  One, multicenter, prospective cohort study (Transthyretin Amyloid 
Cohort Study – TRACS)43, demonstrated in a small (n=29) population that mortality was 
high (29%) and differed between ATTRwt (22%) and Val122Ile (79%).  Larger single 
center studies have not confirmed this difference in survival and multivariate analyses of 
TRACS and the THAOS registry data suggests that cardiac function and not the 
presence of a mutation was independently associated with mortality39, 47, 48. Progressive 
left ventricular dysfunction in ATTR-CA is mediated by physiologic derangements that 
include reduction in chamber capacitance, declines in chamber contractility and 
increases in arterial elastance.48. Patients with ATTRwt-CA have impairments in peak 
VO2 and in a large series from the UK National Amyloidosis Center, a positive troponin 
T, presence of a pacemaker, and NYHA class IV symptoms were associated at baseline 
with a worse outcome44.  Clinically, as ATTR-CA progresses, blood pressure falls due to 
reduction in cardiac output and heart rate increases to compensate for a reduced stroke 
volume. Every 6 months, the mean 6-minute walk distance declined by 25.8 meters, 
NT-pro-BNP increased by 1,816 pg/mL, and left ventricular ejection fraction fell by 
3.2%43.  Cardiac cachexia is particularly common with ATTR-CA, potentially mediated in 
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part by right heart failure, liver congestion, and possibly alterations in bowel flora. 
 
Key point: ATTR has been considered a neurologic disease but data from 
worldwide registries suggest that the heart is the main affected organ in at least 
half of the cases. ATTR cardiac amyloidosis is a progressive disorder associated 
with significantly morbidity and mortality.  
 
Diagnosing Cardiac Amyloidosis 
Is the ECG useful for identifying CA?  Classically, CA is characterized by low QRS 
voltage in spite of an increase LV wall thickness observed with non-invasive imaging. In 
contemporary series, however, the prevalence of low voltage varies with etiology, 
ranging from 60% in AL to 20% in ATTR61, 62. The absence of low QRS voltages does 
not, therefore, preclude CA, especially in patients with ATTRwt in whom left ventricular 
hypertrophy or left bundle branch block is present in up to 30% of patients. The hallmark 
of CA is the disproportion between left ventricular wall thickness and QRS voltages. 
While this relationship can be expressed in a relatively complex way63, it can be 
assessed more simply using left ventricular wall thickness/total QRS voltage ratio64. 
Pseudo-infarction patterns, present in up to 70% of cases, can lead to an initial 
misdiagnosis of coronary heart disease. A significant number of patients develop 
conduction disease and the presence of AV block in an older patient with left ventricular 
hypertrophy should always prompt consideration of CA. 
 
Is there a lab test to diagnose CA? As yet, no blood test can diagnose ATTR-CA. In 
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contrast, in AL, serum and urine immunofixation and quantification of serum free light 
chains in combination have a 99% sensitivity for identifying the underlying substrate for 
AL-CA. Importantly, an abnormal free light chain ratio alone is not specific for AL 
amyloidosis as up to 5% of the population over 65 years of age have a monoclonal 
gammopathy of undetermined significance (MGUS)54. This can lead to a misdiagnosis 
of AL-CA in elderly patients who actually have TTR-related CA and MGUS (up to 10% 
of misdiagnosis even in referral centers)55. In addition, free light chains are filtered by 
the glomeruli, with renal dysfunction resulting in increased serum concentrations. Renal 
dysfunction affects kappa and lambda free chains differently and a wider reference 
range for FLC κ/λ ratio has been proposed for use in patients with advanced renal 
failure65. The broader K/L ratio normal ranges in patients with low GFR makes the 
diagnosis of AL-CA more challenging in patients with renal failure. While many patients 
with renal failure have increased left ventricular wall thickness and serum β2-
microglobulin can be associated with increased wall thickness66, beta-2 microglobulin 
amyloid deposition rarely causes meaningful cardiac dysfunction67. Natriuretic peptides 
tend to be particularly high in CA, often out of proportion from the hemodynamic 
burden56. Circulating light chains exert a direct toxic effect by modulating p38 mitogen-
activated protein kinase, which can directly promote NT-pro-BNP expression.29, 57, 58 
Thus, for the same range of hemodynamic abnormalities, plasma levels of NT-pro-BNP 
are higher in AL compared to ATTRwt and ATTRm56.  An apoptotic effect can cause an 
elevation of troponins, sometimes leading to false diagnoses of acute coronary 
syndrome in patients with CA hospitalized for heart failure. Accordingly, the use of new 
blood tests such as the free light chain assay, NT-pro-BNP and troponin in patients with 
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new onset dyspnea and no obvious etiology may enable the earlier diagnosis of AL-CA. 
This approach is particularly relevant to patients with pre-existing clonal plasma cell 
diseases such as MGUS or smoldering myeloma or in patients with unexplained 
increased wall thickness on echocardiography. 
 
Key point:   
While there is no test diagnostic for CA, there are blood based tests (sequencing 
of transthyrein for ATTR and free light chains/immunofixation for AL) that can 
identify the substrates for this illness??(Just an idea – edit as you see fit) 
 
Should everyone with TTR cardiac amyloidosis have gene sequencing?  TTR 
gene sequencing is recommended in all cases of TTR-related amyloidosis as hereditary 
types of amyloidosis cannot be distinguished from acquired types on clinical grounds 
alone and a family history indicating autosomal dominant inheritance is often absent 
due to incomplete and late disease penetrance. Thus sequencing the transthyretin gene 
in conjunction with genetic counseling is recommended in cases in which hereditary 
TTR is proven by mass spectroscopy or suspected even with a negative profile on mass 
spectroscopy. 
 
Do laboratory tests predict prognosis in CA?  There are well established prognostic 
models in AL amyloidosis. Current staging systems for AL-CA are based on serum 
levels of N-terminal pro-brain natriuretic peptide (NT-pro-BNP), cardiac troponin T, and 
the concentration of circulating free light chains. The combination of the three 
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biomarkers constitutes the most powerful prognostic tool available in AL-CA and is the 
basis for the staging systems elaborated by the Mayo Clinic68 (Figure 1). The scoring 
system assigns one point for each of the following: NT-pro-BNP ≥ 1800 pg/mL, 
Troponin T ≥0.025 ng/mL, and difference between the kappa and lambda free light 
chains ≥ 18 mg/dL. Median survival of stage III patients was only 3.5-4.1 months. Within 
stage III, NT-pro-BNP > 8500 pg/ml combined with a systolic blood pressure less than 
100 mmHg identifies patients with particularly high mortality (Stage III B). However, 
even patients with advanced cardiac amyloid can achieve meaningful improvements in 
survival if the light chains are reduced and accompanied by a cardiac response 
reflected by a decline in NT-pro-BNP response, defined as a decrease in NT-pro-BNP 
of >30% and >300 ng/L assuming a baseline value were ≥650 ng/L.  Such responses 
predict clinical outcome and survival independent of therapy type, treatment class, or 
regimen69. Emerging data, suggest cardiac biomarkers are also a useful prognostic 
marker of cardiac function in ATTR70 
If you like, you can pull the old key point down here from the diagnosis section 
 
What is the role of imaging modalities in diagnosing CA? The diagnosis of cardiac 
amyloidosis should be systematic and directed towards the cause as well as the 
presence of amyloid protein in the myocardium. Laboratory tests, bone-tracer 
scintigraphy, genetic analysis and tissue biopsy all have a place in achieving these 
goals. In clinical practice, cardiac imaging is relevant to CA in three scenarios: (1) 
differential diagnosis of hypertensive hypertrophic and restrictive cardiomyopathy (most 
common); (2) the evaluation of patients known or suspected to have systemic AL or 
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familial TTR amyloidosis; and (3) in the presence of definite CA, to stage the disease 
and monitor the response to therapy. Cardiac imaging must be interpreted alongside 
other clinical findings and different imaging techniques should be considered 
complementary. The question is not what the “best” examination is, but which is most 
useful and appropriate for each step of the diagnostic and therapeutic pathway (Table 
3). 
 
What are the findings on cardiac ultrasound that raise suspicion of CA? The 
echocardiographic findings of CA have been extensively reviewed elsewhere and are 
summarised in Figures 2 and 371-73. Nearly all are non-specific, but in context they can 
be highly suggestive of CA. The major morphological abnormalities in patients with 
advanced disease are symmetrical thickening of the left ventricle, thickening of the free 
wall of the right ventricle and a small pericardial effusion. Classical signs also include 
thickening of the atrioventricular valves and inter-atrial septum and abnormal myocardial 
“texture” characterized as a speckled appearance, although the latter is less reliable 
when using harmonic imaging.  Amyloidosis is the archetype for diastolic LV 
dysfunction, with findings dependent on the stage of disease74. Early cardiac 
involvement is often associated with impairment of relaxation which progresses to 
typical restrictive LV pathophysiology in advanced symptomatic disease. Analogous 
changes in RV diastolic function occur  in the RV inflow, superior vena cava, and 
hepatic vein flow velocities75. CA is often listed as a cause of HFpEF, but this 
underplays its impact on ventricular systolic performance 7, 44, 76-79. While LVEF may be 
normal until the advanced stage of disease, reduction in peak systolic wall motion 
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velocities, especially in the longitudinal axis, are present even in early disease80. In 
general, CA alters strain parameters to a much greater degree than other causes of LV 
hypertrophy and is characterized by a base-to-apex strain gradient (Figure 3, upper 
right panel)78, 79, 81. This is readily appreciated in parametric polar maps that show 
relative apical sparing of longitudinal strain, representing an important diagnostic clue 
differentiating CA from other cardiomyopathies78. In general, differentiating AL from 
ATTR-CA with echocardiography is not possible but on average patients with AL-CA 
tend to be more restrictive while those with ATTR-CA tend to have greater LV wall 
thickness7, 44, 64. 
 
What is the role of cardiac magnetic resonance imaging in diagnosis? Much of the 
structural information derived from CMR is similar to that obtained using 
echocardiography, but the ability to interrogate tissue composition with gadolinium 
based contrast agents has led to an increase in the frequency of diagnosis of CA82-87. 
Gadolinium is a purely extracellular agent and does not enter intact cardiomyocytes82. In 
some cases of CA, there is a virtually pathognomonic appearance of global sub-
endocardial late gadolinium enhancement in a non-coronary artery territory distribution 
with a dark blood pool. However, enhancement can also be diffuse and transmural or 
more localized and patchy82, 84, 88. False negative studies can also arise for technical 
reasons when scans are nulled using abnormal myocardium 83. This latter problem is 
reduced by using phase-sensitive inversion recovery (PSIR) sequence which reduces 
the need for an optimal null point setting and makes scans less operator dependent82, 
89.T1 mapping is a new magnetic resonance technique in which a quantitative signal 
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from the myocardium is measured, before (native T1) or after contrast administration82, 
85, 86. CA substantially increases native T1 and in AL and in ATTR-CA (Figure 3, lower 
right panel). T1 values are higher in AL-CA compared with ATTR-CA, while the 
extracellular volume is higher in ATTR-CA than in AL-CA87. As native T1 requires no 
contrast administration, it can be used in patients with renal impairment and may be 
abnormal before the left ventricular wall thickens. Combined, native T1 mapping and 
measures of extracellular volume (ECV) post contrast can delineate three aspects of CA 
including amyloid burden or infiltration via measure of ECV, edema via measure of 
native T1 and myocyte response via measure of intracellular volume. Such an approach 
can provide a richer understanding of the pathophysiological processes that may be 
used to monitor disease progression and response to therapy. Current limitations of the 
T1 imaging are the effect of confounding pathologies such as myocardial edema and 
platform dependent variation in normal ranges for T1. 
 
What is the role of myocardial scintigraphy in making a specific diagnosis? The 
99mTc-phosphate derivatives, originally developed for bone imaging, were observed to 
accumulate in the early healing phase after acute myocardial infarction. 99mTc-PYP 
imaging was first described as a potential diagnostic test for CA in the early 1980s 
following reports describing increased cardiac uptake in patients with amyloid heart 
disease 90-92. More recently in Europe, studies have evaluated the role of the tracer 
99mTc-3,3-diphosphono-1,2-propanodicarboxylic (DPD) in diagnosing CA (Figure 3, 
lower left panel) 93-95.  Collectively, the data show that ATTR-CA is particularly avid for 
bone tracers, whereas uptake in AL-CA is either absent or only minimal.  The 
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explanation for this differential uptake is unknown, but it has been suggested that the 
preferential binding to ATTR may be a result of higher calcium content. Bone tracers 
seem to be useful for early identification of ATTR-CA and may more closely correlate 
with amyloid load than estimates from CMR 96 Additionally, there is also uptake in 
skeletal muscle, which may appear to suppress bone activity due to masking by 
extensive soft-tissue uptake. In selected patients the specificity of “bone tracer 
scintigraphy for ATTR CA is so high that this method can be considered a “diagnostic 
standard” (see below). 
 
Can PET be used to image and quantify amyloid? 18F-florbetapir is approved for 
imaging beta amyloid protein in the brain. Recent studies have shown that it is also 
taken up in the heart in patients with ATTR-CA and AL-CA (Figure 3, lower right panel). 
Similar findings have been reported for another beta amyloid imaging agent 11C-PiB 97. 
These agents hold  promise for absolute quantification of amyloid burden. 
 
How can one integrate the various imaging modalities into a diagnostic 
algorithm?  A consensus on the role of bone scintigraphy for non-invasive diagnosis of 
CA has emerged (Figure 4). If CA is suspected, blood and urine should be analysed for 
evidence of a plasma cell dyscrasia and imaging with bone tracer considered if ATTR-
CA is a possibility. If these tests are negative, then current evidence suggests that CA is 
very unlikely98. CMR scanning  may be used prior to nuclear scintigraphy as an aid to 
diagnosis, but a 10-20% false negative (particularly in-CA) and false-positive rate87 
(possibly more so in people of Afro-Caribbean ancestry) for conventional contrast 
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enhanced scans means that it does not substitute for other tests. Until very recently, a 
tissue diagnosis was considered essential in all cases of suspected CA. However, in the 
setting of a positive 99mTc-phosphate scan without evidence for plasma clone on blood 
and urine testing, a diagnosis of ATTR-CA can be made without a biopsy. For those 
patients with evidence for a plasma cell dyscrasia, a histologic diagnosis is still required 
as the presence of uptake on a 99mTc-phosphate scan is not 100% specific for ATTR-
CA. 
 
When and how should tissue biopsy be undertaken? The diagnostic accuracy of an 
extra-cardiac biopsy depends on the type of amyloidosis and on the examined tissue. In 
general, the yield of an extra-cardiac biopsy (abdominal fat pad, gingiva, skin, salivary 
gland, or gastrointestinal tract) is higher in AL than in ATTRm; the yield is low in 
ATTRwt. In a series of 131 patients with CA and a positive endomyocardial biopsy 
(EMB), only 73% showed amyloid infiltration on non-cardiac tissue sampling 99.  In 
ATTR, peri-umbilical fat biopsy, especially in patients with ATTRwt has a sensitivity of 
<20%99.  Thus, while a fat pad biopsy is a preferred initial site, a negative result is 
insufficient to exclude the diagnosis and an endomyocardial biopsy should be 
performed. 
 
How does one confirm the precursor protein causing amyloidosis? The ultimate 
goal of a biopsy, in addition to documenting amyloid infiltration, is to provide a definite 
etiological classification. Immunohistochemistry remains the most widely available 
method for fibril typing. Its diagnostic value is very high in AA amyloidosis and in most 
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cases of ATTR amyloidosis, but the results are not always definitive in patients with AL 
amyloidosis. The most frequent pitfall is the coexistence of positivity for more than one 
type of antisera, typically those for TTR and lambda or kappa-chains, which are the 
result of the antibody binding to circulating proteins present in the pathological 
specimen. In a recent series, 8/15 patients with monoclonal gammopathy, showed 
strong TTR staining in the histological samples whereas mass spectrometry 
demonstrated light chain amyloid in 5 of these 8 patients100. Mass spectrometric 
analysis of amyloid is the new gold standard for fibril typing6. This method involves laser 
micro-dissection and laser capture of amyloid using a microscope followed by tryptic 
digestion and tandem mass spectrometry. Computer algorithms match the peptides to a 
reference database, where amyloid fibril subtype can be identified.  Frequently, mass 
spectroscopy can identify a mutant TTR genotype, though when a mutation is not 
identified, gene sequencing may be necessary. 
 
Key point: Tissue diagnosis is required for AL amyloid and endomyocardial 
biopsy should be pursued if index of suspicion is high despite a negative fat pad. 
Nuclear scintigraphy agents combined with assessment for monoclonal proteins 
are reducing the need for tissue confirmation in ATTR; CMR characterization of 
myocardial tissue can be used to monitor disease progression and response to 
therapy. 
 
Standard and Emerging Therapies for Cardiac Amyloidosis 
Are there specific treatments for CA? Diagnosis and clinical care have been held 
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back by the erroneous belief that there are limited effective treatments for AL-CA and by 
the absence of disease modifying therapy for ATTR-CA. It is now recognized that a 
reduction in the precursor proteins that forms amyloid fibrils is the key to improving 
prognosis in CA. Combination chemotherapy is  effective in lowering free light chains in 
AL-CA and orthotropic liver transplantation to remove the hepatic source of genetically 
variant amyloid-forming proteins either alone or in combination with cardiac transplant 
has a role in selected patients with ATTRm-CA. TTR stabilizers and silencers hold  
promise for managing all forms of ATTR-CA and newer anti-fibrillar therapies aimed at 
reversing cardiac dysfunction are in clinical trials. The key determinant of the efficacy of 
therapy is the severity of disease at diagnosis. In advanced disease, therapy is poorly 
tolerated and often ineffective24. Multidisciplinary team management and supportive 
care is critical in controlling symptoms, optimizing nutritional status, maintaining cardiac 
function and managing the toxicities of treatments.  Collectively, therapeutic advances 
have begun to shift CA from a universally fatal disease to a manageable chronic 
condition. 
 
AL Cardiac Amyloidosis 
What are the goals of therapy for AL cardiac amyloidosis? The toxic amyloid-
forming light chains that cause AL are produced in the bone marrow and the clonal 
plasma cells in AL possess many of the same genetic abnormalities found in other 
plasma cell dyscrasias 102-105. The major difference between AL and myeloma is that in 
AL organ damage occurs because of the monoclonal light chains while in myeloma the 
organ damage is due largely to cell mass106.  Anti-plasma cell treatments for AL have 
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evolved from those used  in myeloma, including steroids, high-dose melphalan, 
proteasome inhibitors  and immunomodulatory agents 107. The goals of therapy in AL-
CA are to eliminate the clonal plasma cells and provide optimal supportive care to 
address and control side effects of therapy. Patients with advanced cardiac involvement 
cannot tolerate high-dose therapy with autologous stem cell transplantation (SCT) and 
therefore patient selection for SCT has become restrictive49, 108.  Despite excellent 
hematologic response rates, patients with elevations of cardiac biomarkers who are 
poor candidates for SCT are also at significant risk even with standard bortezomib-
based therapy with 40% dead within 2 years of diagnosis and only 20% of responders 
experiencing cardiac improvement by biomarker criteria109. However, when a response 
is achieved survival can be meaningfully improved. 
 
Is halting deposition of amyloid the only treatment or can removal of amyloid and 
reversal of organ dysfunction be achieved? Hematologic response and degree of 
cardiac involvement are the deciding factors regarding overall survival in systemic AL 
amyloidosis4. The categories of hematologic response with initial therapy in newly 
diagnosed patients are complete (CR, normal FLC ratio and negative serum and urine 
immunofixation), very good partial response (VGPR, difference between involved and 
uninvolved free light chains < 40 mg/L or <4 mg/dl), partial response (PR, difference 
between uninvolved and involved free light chains decreased > 50%), and no response 
(NR)25. The frequency of cardiac responses defined as a decline in NT-pro-BNP to 
<30% of baseline and of at least 300 pg/ml in 374 newly diagnosed treated AL-CA 
patients were 57% with a CR, 37% with a VGPR, 18% with a PR and 4% with NR25 
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(Figure 1). At 6 months after starting anti-plasma cell chemotherapy, cardiac responses 
occurred in 26% and progression in 45% of patients, with 85% of responders and 30% 
of progressors still alive after 2 years25.  Such data indicate that anti-plasma cell 
chemotherapy, including the use of high-dose chemotherapy with SCT, does not enable 
reliable cardiac improvement for all patients especially those with advanced cardiac 
involvement. Many patients with hematologic responses continue to have persistent 
cardiac dysfunction despite improved overall survival. After initial therapy, the median 
hematologic progression-free survival (PFS) is 1 to 4 years, depending on the type of 
initial therapy. The PFS for the 25% of newly diagnosed patients who were candidates 
for SCT appears to be higher than that of patients receiving standard therapy with 
bortezomib-based combinations. Indeed, about 80% of the long-term post-SCT 
survivors with CR have organ responses.49. At hematologic relapse, the majority of 
patients have stage 2 or 3 chronic renal disease and stage 2 cardiac disease (see 
Figure 1)30. 
The unmet need for patients is therapy that reverses organ damage and 
dysfunction36.  Several approaches are in clinical trials at this time, including three 
monoclonal antibody based therapies that may enhance phagocytic clearance of 
amyloid deposits.  The anti-amyloid 11-1F4 monoclonal was used in a phase I trial 
(NCT02245867) in AL patients with relapsed refractory disease, and cardiac and GI 
organ responses were reported in 3 of the first 6 patients treated50. Employing a 
different approach in their phase I trial (NCT01777243), based on the fact that amyloid 
fibril deposits always contain the non-fibrillar normal plasma protein, serum amyloid P 
component (SAP), investigators from the National Amyloidosis Center in the UK used a 
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combination of two agents. The drug, R-1-[6-[R-2-carboxy-pyrrolidin-1-yl]-6-oxo-
hexanoyl] pyrrolidine-2-carboxylic acid (CPHPC), efficiently depletes SAP from the 
plasma but leaves some SAP in amyloid deposits that can be specifically targeted by 
therapeutic IgG anti-SAP antibodies, inciting an inflammatory multinucleated giant cell 
response51. In this phase I trial, whole-body scans using iodinated SAP demonstrated 
depletion of hepatic amyloid in 50% of patients with liver involvement. There were also 
reductions in in C3 and spikes in CRP, indicating ongoing inflammation. Patients with 
cardiac involvement were excluded from the trial52. The third, and furthest along in 
clinical development, is the anti-amyloid monoclonal NEOD001 that binds to an epitope 
in amyloid fibrils. In a phase 1/2 trial (NCT01707264), previously treated AL patients 
who were in hematologic remission with biomarker evidence of on-going organ damage, 
received NEOD001 monthly53. There were no toxicities and organ responses were seen 
in majorities of both cardiac (57%) and renal (60%) patients. NEOD001 is now in a 
phase 3 trial for newly diagnosed patients with cardiac involvement (NCT02312206), in 
which patients receive bortezomib-based therapy and are randomized to receive either 
NEOD001 or saline monthly. 
What are the mechanisms of therapeutic efficacy (reduction in precursor 
protein/amyloid production versus amyloid clearance)? Therapeutic efficacy in AL 
has two dimensions, survival and improvement in organ function. Hematologic response 
to therapy is measured in terms of the reduction or elimination of the clonal plasma cells 
that produce the culprit light-chain protein. Patients who achieve a hematologic CR or 
VGPR live longer than those who do not25. Improvement in organ function is measured 
with cardiac and renal biomarkers and, for patients with other organs involved, with a 
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mix of exam and laboratory findings such as normalization of orthostatic symptoms and 
vital signs for patients with autonomic neuropathy or of  liver span and alkaline 
phosphatase for those with hepatic involvement110. Patients who achieve cardiac 
biomarker responses live longer than those who do not 25, 60, 111. 
 Hematologic responses based on changes in the serum free light chain assay 
are validated surrogates for the impact of therapy on the clonal marrow cells. With 
elimination or near elimination of the culprit light-chain protein, patients usually 
experience improvement in organ function and in their QOL. However, while 
hematologic response is necessary for organ response, it is not sufficient36. There is 
general consensus that both early cardiac death and survival with persistent organ 
damage are critical unmet clinical challenges. 
 
What factors influence treatment decisions (rapidity of response, toxicity and 
physiologic reserve)?  The initial evaluation of newly diagnosed patients with AL is 
focused on the extent of both cardiac and extra-cardiac organ involvement, physiologic 
reserve and the character of the clonal marrow plasma cells26. In a cohort of over 800 
patients from 6 countries, 26% were NYHA class 2 or 3, 25% CKD Stage 3, and 15% 
CKD Stage 4 or 5; 50% were Mayo cardiac stage II with either Troponin T or NTpro-
BNP above the threshold and 34% were cardiac stage III with both elevated; 19% had 
liver and 16% peripheral nervous system involvement25. 
 
Who is eligible for SCT? Eligibility criteria for high-dose therapy with SCT include age 
less than 65, Karnofsky performance status of 80% or higher, adequate cardiac function 
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(systolic blood pressure > 90 mm Hg, ejection fraction >45%, troponin T <0.06 ng/ml, 
NT-proBNP < 8,500 pg/ml or pulmonary artery saturation of >55%) and compensated or 
controlled orthostatic changes in blood pressure113.  Patients who are Mayo cardiac 
stage III or CKD 4 are rarely eligible; young patients on hemodialysis, however, who are 
cardiac stage I or II are often eligible for SCT.  Most patients are not eligible for SCT 
and receive bortezomib-based therapy with doses adjusted for frailty, impaired liver 
function and NYHA class114, 115. Bortezomib may not be the first choice of proteasome 
inhibitors for patients with peripheral neuropathy because of the risk of worsened 
neuropathy due to the drug; alternatives exist116.  After SCT, consolidation is 
recommended for AL patients who do not achieve a CR (in myeloma post-SCT 
consolidation is recommended for all)4, 117. For patients treated with bortezomib-based 
therapy, the lack of a hematologic response after 2 cycles is usually a signal to change 
therapy and, in most cases, bortezomib and dexamethasone will be retained but other 
agents such as melphalan or immune-modulatory drugs are added26.  
 
What is the data on efficacy of therapies? The mix of therapies used to treat newly 
diagnosed patients with AL and the reported outcomes are recounted in Supplementary 
Table 1. High-dose therapy with SCT and bortezomib-based combination chemotherapy 
are the two options used most frequently in the USA108. In the UK and EU, however, 
SCT is less often employed and other regimens such as oral melphalan and 
dexamethasone or oral cyclophosphamide, thalidomide and dexamethasone are 
commonly used107, 118, 119. Doses of agents in all of these regimens are often adjusted 
for age, frailty, renal and hepatic function, and NYHA class. 
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Key point: New targeted plasma cell therapies have rapidly expanded the 
treatment option for patients with AL cardiac amyloid, improving outcomes for 
patients with earlier stage disease. 
 
ATTR Cardiac Amyloidosis 
What are the targets for therapy in TTR?  Current treatment for ATTR-CA is 
focused on various stages in the TTR amyloid cascade including silencing of TTR 
production, TTR stabilization and amyloid clearance from tissues (Figure 5)120-
122.Because 95% of TTR protein is produced by the liver, orthotopic liver transplantation 
(OLT) has been employed in ATTRm to replace amyloid forming mutant with wild type 
TTR and theoretically arrest amyloid formation. The majority of OLTs for ATTRm 
amyloid are performed in patients with a primary neuropathic phenotype, most 
commonly the Val30Met variant123. OLT is considered a preventative measure to 
forestall the development of the sensorimotor neuropathy or multiple organ involvement. 
Survival after liver transplantation in Val30Met patients is > 50% at 20 years123. Since 
the liver function of TTR liver transplant recipients is otherwise normal, their livers have 
been transplanted into high risk recipients (“domino liver transplant”), causing TTR 
amyloidosis in recipients several years later124.  While survival is prolonged by liver 
transplantation123, there is slowing but not arrest of cardiac dysfunction.  This is 
attributed to deposition of wild type TTR amyloid in the heart from the transplanted liver 
causing progressive cardiac dysfunction.  Patients with fragmented ATTR fibrils (type A) 
developed HF after OLT while those who had intact ATTR fibrils (type B) did not 
deteriorate to the same degree127. The scarcity of organ availability, the need for lifelong 
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immunosuppression and the relatively older age of affected subjects make 
transplantation an a suboptimal option for treating ATTR-CA. 
Both RNA interference (RNAi) and antisense oligonucleotides (ASOs) have been 
used to inhibit hepatic expression of amyloid forming TTR.  These therapies capitalize 
on endogenous cellular mechanism for controlling gene expression in which siRNAs or 
ASOs, mediates the destruction of target messenger RNA (mRNA) essential for TTR 
protein production. These agents cause a robust and durable reduction in genetic 
expression (knockdown) of TTR and retinol binding protein128-130.  Both methods of 
silencing have completed recruitment for phase III trials in ATTR peripheral neuropathy 
with results expected in 2017 but a phase III trial in ATTR cardiomyopathy was recently 
suspended with unexpected adverse impact on those receiving active treatment 
(Supplementary Table 2).  
TTR stabilizers have demonstrated efficacy in FAP131, 132 but their role in ATTR-
CA is unknown. Diflunisal, a nonsteroidal anti-inflammatory drug, binds and stabilizes 
common familial TTR variants against acid-mediated fibril formation in vitro and has 
been tested in human clinical trials131. Use of diflunisal is controversial given the known 
consequences of chronic inhibition of cyclooxygenase enzymes including 
gastrointestinal bleeding, renal dysfunction, fluid retention, and hypertension that may 
precipitate HF in vulnerable individuals. Tafamidis is a novel compound that binds to the 
thyroxine-binding sites of the TTR tetramer, inhibiting its dissociation into monomers133 
and blocking the rate-limiting step in the TTR amyloid forming  cascade (Figure 5).  
Doxycycline disrupts fibril formation134 and when combined with the bile salt, 
tauroursodeoxycholic acid, demonstrated a synergistic effect on removal of tissue TTR 
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deposits in an animal model, leading to open  label trials in humans135.  Epigallocatechin 
gallate (EGCG), the most abundant flavonoid in green tea, inhibits amyloid fibril 
formation in vitro, leading to open label trials in ATTR-CA136, 137. 
 
What are the results of recent trials in TTR?  A majority of the trials completed to 
date have been small (<100 subjects), phase II, open label, intermediate duration (1-2 
years) with primary endpoints being the NIS-LL and QOL for ATTR peripheral 
neuropathy and echocardiographic, biomarkers and six minute hall walk for ATTR-CA  
(Supplementary Table 2). Trials for neuropathy are further along than those for 
cardiomyopathy. Trials to date have demonstrated safety of the compounds, in the short 
term, with efficacy limited to either a surrogate maker (TTR stabilization) and/or the 
absence or slowing of disease progression, albeit with no control group. 
The only phase III trials completed to date involved administration of diflunisal131 
and tafamidis132, 138, both in FAP. In the diflunisal trial, echocardiography demonstrated 
a prevalence of presumptive CA in >50% of these FAP patients but analysis of 
echocardiographic variables including strain did not show significant differences ? after 
treatment, though  statistical power was low139. Tafamidis, in patients with early-stage 
ATTRm due to Val30Met132, slowed progression of neurological symptoms and early 
treatment was associated with greater preservation of neurologic function138, which was 
not confirmed in late phase FAP140.  Thus, early administration of tafamidis seems to be 
important for its efficacy. Additionally, all previous trials employed a dose of 20 mg but 
an 80 mg dose is being tested in an ongoing phase III trial, with biochemical data 
suggesting that a higher dose may be required for TTR stabilization141.  Five year safety 
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data in a small cohort has been reassuring in that tafamidis was generally well tolerated 
at 20 mg, though efficacy data showed few patients with ATTR-CA were clinically 
stabilized at 3.5 years. 
 
What therapies are in late phase development? Currently there is 1 clinical trial for 
ATTR-CA in Phase III involving tafamidis.  A second trial with revusiran, a siRNA, was 
recently stopped and the development of the drug suspended. Both of these trials were 
placebo controlled with allocation to active therapy of ~2:1 and a fixed study duration 
that encourages participation by subjects who have a progressive, life threatening 
condition.  Differences in study populations include a focus on ATTRm in the case of 
revusiran while the other (ATTR-ACT) enrolled both ATTRm and ATTRwt. The ATTR-
ACT trial of tafamidis is expected to conclude in 2018.  
Key point: The biologic process underlying ATTR-CA has led to the development 
of numerous therapies that are currently in late phase clinical trials. A recent trial 
of a siRNA for transthyretin in CA was stopped prematurely due to an unexpected 
worsening of subject’s clinical status.  
 
Cardiac Replacement therapy – Transplant and VAD  
Is AL amyloidosis a contraindication to cardiac transplantation? CA from AL 
amyloid was previously considered a contraindication to orthotopic heart transplant 
(OHT) because of concerns regarding worse long term outcomes due to the amyloid 
involvement of other organs or the risk of recurrent amyloid in the graft142. However, the 
development of multiple therapies targeted at the monoclonal protein including high 
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dose chemotherapy with SCT has made long term control of the plasma cell dyscrasia 
possible. Accordingly, series in selected patients for whom heart transplant was 
performed at experienced centers with established multi-disciplinary collaborations 
followed by either stem cell transplant or ongoing chemotherapy have reported 
outcomes comparable to other subjects with restrictive cardiomyopathies.143-146 
Additionally, an analysis of UNOS data shows improved post-OHT survival in patients 
with CA, in part due to improved patient selection including an increase in those with 
ATTR-CA.146. The one year survival post OHT in UNOS for CA (? Is this specific to AL 
or also includes TTR?)  from 2010 to 2012 was 81.6%.  Accordingly, current guidelines 
endorse consideration of selected patients with either  AL and ATTR-CA147. 
 
What additional testing is required for transplant  evaluation? The degree of 
organs involved is an important prognostic variable influencing the outcomes of patients 
with AL undergoing SCT.  Accordingly, multiple other organ systems must be thoroughly 
assessed for the functional effect of amyloid and if necessary for the anatomic/histologic 
degree of amyloid infiltration.  Specific guidelines by the ISHLT have been published 
(see  Table 4).147 
 
Do outcomes differ in subjects with AL vs. TTR cardiac amyloidosis undergoing 
OHT? Data from Columbia University Medical Center, has shown better survival for 
ATTR-CA subjects (n=10) than AL-CA (n=16) undergoing OHT with transplants 
performed mainly from 1999-2008.  However, a more contemporary series from 
Stanford has shown better survival in AL (n=10) than TTR (n=9) CA145. Multicenter data 
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obtained as part of the International Consortium in Cardiac Amyloid Transplantation 
(iCCAT) has demonstrated that outcomes of patients with CA do not differ statistically 
from those with AL compared to TTR148. 
 
How should the plasma clone be managed in patients with AL cardiac amyloid 
undergoing OHT? Control of the underlying plasma cell dyscrasia is critical to 
successful outcomes in AL cardiac amyloid.  Data from iCCAT demonstrates that 
survival without recurrent amyloid post OHT is higher in those who receive 
chemotherapy prior to OHT than those who did not receive chemotherapy149. 
Accordingly, upfront plasma cell therapy to achieve a complete or very good 
hematologic response while waiting for OHT is increasingly being advised. While high or 
dose adjusted melphalan with SCT remains the most cytotoxic therapy for AL amyloid, 
combination therapy using proteasome inhibitors has been shown to be effective in AL-
CA patients post OHT145. 
 
How can I bridge my patient with advanced cardiac amyloid to an OHT? The 
options for mechanical circulatory support as a bridge to OHT for CA patients is 
confounded by the small ventricular chamber size and increased wall thickness that 
increase the risk for suction events, right heart failure and overall worse outcomes in 
very small series reported to date.150 Survival with a VAD is strongly associated with left 
ventricular end diastolic diameter151. Other forms of circulatory support including intra-
aortic balloon pump,  BiVAD or total artificial heart (the latter employed given the need 
for biventricular support) have been employed though survival at one year is reduced if 
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circulatory support is required152.  A theoretical analysis using a cardiovascular 
simulation of a novel micro-VAD for CA has shown that sourcing of blood from the left 
atrium was not associated with suction, as assessed by declines in left ventricular end 
systolic volumes, but did lower left atrial pressure and increase cardiac output and blood 
pressure in subjects154.  Whether such an approach can be effective in-vivo in CA 
requires additional study. 
 
Key point: While the overall goal is to eliminate the need for OHT in CA, advances 
in patient selection and available therapies have made intermediate term 
outcomes of OHT in CA comparable to non-amyloid patients. 
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Figure Legends 
Figure 1: Mayo staging system for risk stratifying subjects with AL-CA in which one 
point is assigned for each of the following: NT-pro-BNP ≥ 1800 pg/mL, Troponin T 
≥0.025 ng/mL, and difference in serum free light chains ≥ 18 mg/dL. Those with highest 
score have the worst prognosis68 (Panel A).  
Survival from the 3-month landmark of 300 patients with AL amyloidosis based on 
hematologic response. The proportion of stage III patients was not significantly different 
among the four hematologic response groups. CR, complete response; NR, no 
response; PR, partial response; VGPR, very good partial response and py, person-year; 
25 (Panel B).   
Prognostic relevance of cardiac response and progression criteria showing survival from 
the 6-month landmark of 377 patients with immunoglobulin light chain (AL) amyloidosis 
and baseline N-terminal natriuretic peptide type B (NT-proBNP)>650 ng/L according to 
NT-proBNP response and progression25 (Panel C).  
Survival according to NT-proBNP response in an ongoing phase 3 trial comparing 
melphalan-dexamethasone with melphalan-bortezomib-dexamethasone 
(NCT01277016)101 (Panel D). 
 
Figure 2: Sequence of still images showing typical echocardiographic features of 
cardiac amyloidosis. A: 2-D Parasternal long axis showing concentric left ventricular 
hypertrophy, bright myocardium and left atrial dilatation. B: 2-D Parasternal short axis 
showing concentric left ventricular hypertrophy and bright myocardium. C: 2-D Apical 
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four chamber view showing concentric left ventricular hypertrophy and biatrial dilatation 
D: Pulsed wave Doppler of mitral inflow showing an increase in E/A ratio, normal E 
wave deceleration time but a marked reduction in transmitral A wave velocity. E: Pulsed 
wave Doppler of pulmonary vein inflow showing marked diastolic prominence and 
increased duration and peak velocity of atrial reversal compared to the transmitral 
signal. F: Pulsed tissue Doppler of the lateral mitral annulus showing marked reduction 
in apical systolic and diastolic velocities (normal velocities being: ??, respectively). 
Images courtesy of Dr Leon Menezes, University College London, UK 
 
Figure 3: Upper left panel: Subcostal 2D echocardiogram showing some the typical 
findings in advanced cardiac amyloidosis. A: Biatrial enlargement, B: Thickened 
interatrial septum (and valves), C: Thickening of RV free wall and D: Concentric LVH 
and hyperechoic myocardial texture; Upper right panel: Apical 4-chamber peak systolic 
strain image illustrating relatively well-preserved apical strain with significant basal 
impairment. This is seen in the series of curves and the bull’s-eye color-coded strain 
image, Lower left panel: Patient with atrial fibrillation and moderate to severely impaired 
LV function. Echocardiogram showed increased myocardial density and concentric LVH 
with moderate aortic stenosis. Cardiac MRI showed biventricular hypertrophy, moderate 
aortic stenosis, and diffuse fibrosis, in excess of that expected for LVH and aortic valve 
disease. A) Early whole body planar DPD image. B) 3h Delayed whole body planar 
image showing cardiac retention of racer and reduced bony uptake; Perugini Grade 2. 
C), D), and E) 2 chamber, short axis, and 4 chamber PSIR LGE cardiac MR images 
34 
 
showing diffuse fibrosis. Images courtesy of Dr Leon Menezes, University College 
London, UK,  
Lower right panel: Fused Florbetapir PET/MR imaging. A) Native T1 map shows high 
(>1400) values pre-contrast. B) ECV map, the ECV/interstitial space expansion is as 
high as blood. C) LGE image- There is differential fibrosis, between the ‘core’ of the 
interventricular septum and the epi- and endocardial borders (white vs red arrows) and 
also in the lateral wall, which implies a non-uniform amyloid distribution. D) Fused 
Florbetapir PET/MR uptake with a LV basal septal predominance. Images courtesy of 
Dr Leon Menezes, University College London, UK 
Figure 4: Diagnostic algorithm for patients with suspected amyloid cardiomyopathy. The 
grading system for bone scintigraphy is Grade 0 – absent cardiac uptake; Grade 1 – 
mild uptake less than bone; Grade 2 - moderate uptake equal to bone; Grade 3 - high 
uptake greater than bone. AApoA1 indicates apolipoprotein A-I; DPD, 3,3-diphosphono-
1,2-propanodicarboxylic acid; HDMP, hydroxymethylene diphosphonate; and PYP, 
pyrophosphate (from Gilmore, Circulation 201698) 
 Figure 5: Disease modifying targets in TTR cardiac amyloidosis  
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Table 1: Red Flags and caveats in cardiac amyloidosis 
• A high index of suspicion is mandatory for the recognition of CA (i.e. if you don’t 
think of it you won’t diagnose it) 
• Cardiac amyloid should be suspected in any patient with heart failure, 
unexplained increased LV wall thickness and a non-dilated LV 
• In a patient with a suspicion for HCM, look for the infiltrative features that suggest 
amyloid such as ….(AV block) 
• A distinctive sign of CA is the abnormal ratio between LV thickness and QRS 
voltages rather than low QRS voltages alone. The absence of low QRS voltages 
doesn’t rule out a CA and up to 20% of subjects with CA can have 
electrocardiographic evidence of left ventricular hypertrophy. 
• In an elderly man with unexplained symmetric left ventricular hypertrophy, 
especially in the absence of hypertension, always consider the possibility of 
ATTRwt-CA 
• CA in an elderly patient with a monoclonal gammopathy is not necessarily due to 
AL: consider the possibility of ATTRwt and MGUS 
• Longitudinal LV function can be severely depressed despite a normal LVEF and 
the myocardial contraction fraction (MCF) is often low suggesting reduced global 
myocardial shortening. 
• Myocardial deformation is reduced in cardiac amyloidosis but the apex is 
generally spared  
• On cardiac MRI both T1 signal abnormalities and marked extracellular volume 
expansion in patients with LV hypertrophy are strongly suggestive of CA. LGE 
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distribution is heterogeneous and sub-endocardial enhancement is not the only 
pattern. 
• A history of bilateral carpal tunnel syndrome in a man with HCM-like phenotype 
on echo is highly suggestive of ATTRwt-CA 
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Table 2: Phenotypic findings in AL-CA and in the most frequent types of ATTR-CA 
 AL 
44, 64 
ATTRwt 
39, 42, 44 
Val122Ile 
39 
Ile 68Leu 
37 
Thr60Ala 
155 
Median age at diagnosis 
(yr) 
62 76 70 70 62 
Males (%) 66% 95% 75% 75% 70% 
Common ethnicity Variable Caucasian Afro-
American 
Caribbean 
Caucasian 
(Italy) 
Caucasian 
(USA 
Ireland) 
Cardiac referral route (%) 65 >80 >80 >80 30 
IVS/PW (median values)  15/14 18/17 17/17 17/16 17/17 
LVEF -% 56 50 50 50 53 
Low QRS voltages (%) 45 33 45 30 16 
Peripheral sensory-motor 
neuropathy (%) 
10-20 <10 15 25% 54 
History of carpal tunnel 
syndrome (%) 
<10 30-45 30 37 Unknown 
Autonomic symptoms (%) 24 12-20 10 <10 75 
Median survival  (yr) Depends 
on stage 
3.5 2-3 4-5 3.5 
NTproBNP pg/L (median) ↑↑↑ ↑↑ ↑ ↑ ↑ 
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Table 3: Diagnostic Tests and Their Role in the Various Phases of Evaluation and 
Management of Cardiac Amyloidosis 
 
Imaging and biomarkers of Cardiac Amyloidosis 
Phase of work-up ECHO MRI* “Bone tracers” 
scintigraphy 
BNP 
Suspicion 
Definite diagnosis 
Etiologic diagnosis 
Early diagnosis 
Functional evaluation 
Prognostic stratification 
Amyloid burden 
Response to therapy 
+++ 
+/- 
+/- 
+/- 
+++ 
++ 
- 
+/ 
++ 
++ 
+/- 
+/- 
++ 
+ 
++ 
+/- 
+/- (TTR) 
+++ (TTR) 
+++ 
++ (TTR) 
+ (MIBG) 
+ 
+/- 
+/- 
++ 
- 
+/- 
+/- 
+/- 
+++ 
- 
+++ (AL) 
*T1 native, LGE ECV, TTR – useful for TTR amyloid, MIBG - iodine-131-meta-
iodobenzylguanidine,  
+++ = very useful, recommended, ++= useful, to be considered, += possibly useful  
+/- = role uncertain, - = not useful.  
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Table 4: Recommendation for Evaluation of Extra-cardiac Organs in AL Amyloid 
Prior to OHT according to ISHLT Guidelines  
Organ System Screening Tests 
Pulmonary Pulmonary function testing including arterial oximetry, diffusion 
capacity  
CXR and CT to assess for interstitial disease, effusions   
Thoracentesis may be necessary to differentiate amyloidosis from 
heart failure 
Gastrointestinal Nutritional assessment including pre-albumin, albumin. 
Assessment for bleeding by esophagogastroduodenoscopy, 
colonoscopy  
Assessment of amyloid deposition on random biopsy  
Assessment of intestinal motility with gastric-emptying studies 
Hepatic Serum alkaline phosphatase and bilirubin. 
An alkaline phosphatase >1.5 above upper limit of normal 
in the absence of congestion should prompt liver biopsy to 
assess for portal and parenchymal amyloid deposition.  
Renal Measured creatinine clearance or eGFR and 24-hour urinary 
protein excretion. 
An eGFR or measured creatinine clearance <50 
ml/min/1.73 m2 in the absence of decompensated heart 
failure or urinary protein excretion >0.5 g/24 hours should 
prompt renal biopsy to assess the renal amyloid burden. 
Coagulation Factor X and thrombin time  
Patients with a severe(<25%) factor X functional deficiency 
have o 50% survival after ASCT 
 
Adopted from J Heart Lung Transplant. 2016 Jan; 35(1):1-23). 
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